{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"13"}]}],"title":"Progressive disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Assessments of response were made using the International Myeloma Working Group (IMWG) response criteria and were assessed by magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET)/CT scans (when applicable). Per IMWG response criteria, objective response could be defined as follows: complete response (CR), disappearance of any soft tissue plasmacytomas; partial response (PR), a \\>50% reduction in size of soft tissue plasmacytomas; progressive disease (PD), definite development of new or a definite increase of size of existing soft tissue plasmacytomas; and stable disease (SD), not meeting criteria for CR, PR, or PD.","groups":[{"description":"Participants received 375 mg ONC201 once weekly in combination with 20 mg dexamethasone.","id":"OG000","title":"Phase 1: 375 mg ONC201 + 20 mg Dexamethasone"},{"description":"Participants received 625 mg ONC201 once weekly in combination with 20 mg dexamethasone.","id":"OG001","title":"Phase 2: 625 mg ONC201 + 20 mg Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"The response assessment data reported was conducted at the last on-study visit (end of treatment/follow-up), up to a maximum of 7 months following treatment initiation.","title":"Response of Participants at Last On-study Visit (End of Treatment/Follow-up)","type":"PRIMARY","unitOfMeasure":"Participants"}